|
Match
|
Document |
Document Title |
|
|
10734117 |
Apparatuses and methods for determining a patient's response to multiple cancer drugs
Apparatuses (including devices and systems) and methods for determining if a patient will respond to a variety of cancer drugs. |
|
|
10732184 |
Diagnosis of cancer by detecting auto-antibodies against PAR1
The present invention relates to a method for diagnosis of a cancer, comprising the steps of (i) determining the level of antibodies against protease-activated receptor 1 (PAR1) in a sample from a... |
|
|
10732182 |
Method for predicting cancer sensitivity
The present invention relates to methods of determining cancer cell sensitivity to treatment by using antibodies that specifically bind to and detect the presence of a Bcl-2 heterodimer protein,... |
|
|
10731224 |
Enhancement of cancer screening using cell-free viral nucleic acids
Cell-free DNA molecules in a mixture of a biological sample can be analyzed to detect viral DNA. Methylation of viral DNA molecules at one or more sites in the viral genome can be determined.... |
|
|
10731221 |
Diagnosing IDH1 related subgroups and treatment of cancer
The invention relates to classification, diagnosis and treatment of cancers. In one embodiment, the present invention provides methods and kits that classify cancers into various subtypes based on... |
|
|
10731162 |
Methods relating to circulating tumor cell clusters and the treatment of cancer
Described herein are methods and assays relating to the presence and/or level of circulating tumor cells (CTCs). These CTC-Cs represent a highly metastatic subpopulation of CTCs. In some... |
|
|
10731134 |
Production method for artificial cancer stem cell and induced differentiation method therefor
It is intended to provide a cancer stem cell and a method for preparing the same. The present invention provides a method for preparing a pluripotent cancer stem cell, comprising transferring... |
|
|
10731128 |
Compositions and methods for in vitro activation and expansion of serial killer T cell populations and passive immunization of a cancer patient with tumor cell killing cells
The described invention provides a method for in vitro immunoactivation of mononuclear cells by contact with one or more populations of engineered leukocyte stimulator cells genetically engineered... |
|
|
10730903 |
Adenosine analogs as methyltransferase inhibitors for treating cancer
Compounds having methyltransferase inhibitory activity are disclosed. The compounds have the structures The compounds disclosed are useful in the treatment of cancer and similar diseases... |
|
|
10730840 |
Substituted tetrahydroisoquinoline ethylbenzamide anti-cancer agents
The compounds herein disclosed are N-substituted tetrahydroisoquinoline ethylbenzamide compounds that have modifications on the phenyl rings by introducing groups with various electronic... |
|
|
10729766 |
Method for improving the efficacy of a survivin vaccine in the treatment of cancer
The present invention provides methods for improving the efficacy of a vaccine in the treatment of cancer. The methods of the invention comprise the administration of at least two doses of an... |
|
|
10729755 |
Peptides and combination of peptides for use in immunotherapy against pancreatic cancer and other cancers
The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The... |
|
|
10729752 |
Compositions and methods for treating cancer with arginine depletion and immuno oncology agents
Methods of treating tumors or cancer include administration of an arginine depleting enzyme and an immune-oncology agent. |
|
|
10729739 |
Methods of treating prostate cancer with GnRH antagonist
The invention provides methods and dosing regimens for safely and effectively treating androgen-dependent prostate cancer with a gonadotrophin releasing hormone (GnRH) antagonist without causing a... |
|
|
10729713 |
Pharmaceutical composition for treating hepatitis, liver fibrosis, and liver cancer
The present invention relates to a pharmaceutical composition for treating hepatitis, liver fibrosis, and liver cancer, which comprises the following components in parts by weight: 0.15-10 parts... |
|
|
10729699 |
Methods of treating castration-resistant prostate cancer with glucocorticoid receptor antagonists after anticancer therapy
Embodiments of the invention are directed to the treatment of subjects with prostate cancer, in particular those with castration resistant prostate cancer, with glucocorticoid receptor... |
|
|
10729692 |
Dual inhibition of CDK and HSP90 destabilize HIF1alpha and synergistically induces cancer cell death
The present disclosure provides pharmaceutical compositions including a CDK inhibitor and an HSP90 inhibitor, as well as methods of treating cancer or a tumor in a subject by administering a CDK... |
|
|
10729689 |
Carbazole EHop-016 derivatives as anti-cancer and anti-migratory agents
A series of novel EHop-016 derivatives is presented herein via designing and synthesizing compounds that mimics its more favorable “U-shaped” conformation that appears to be critical for... |
|
|
10729671 |
Zinc complexes of hydrazones and (thio)semicarbazones and their use for the treatment of cancer
The invention provides complexes of Zn2+ of formulae (la) and (IIa) that are useful for treating cancer, as well as compositions and kits comprising such complexes. |
|
|
10729669 |
Compositions and methods for treating cancer
The invention provides compositions and methods to treat a hyperproliferative disorder with phenyl butyric acid (PBA) or a pharmaceutically acceptable salt thereof and an anti-cancer composition. |
|
|
10725053 |
Prostate cancer-associated secreted proteins
Methods are provided for treating a subject with prostate cancer and/or diagnosing a subject at risk for prostate cancer, which can include measuring increased expression of at least two prostate... |
|
|
10725051 |
Multiplex MRM assay for evaluation of cancer
The current disclosure provides specific peptides, and derived ionization characteristics of the peptides from the estrogen receptor (ER), progesterone receptor (PR), and/or antigen Ki67 (Ki67)... |
|
|
10725045 |
Quantifying MGMT protein for optimal cancer therapy of glioblastoma
Methods are provided for treating a cancer patient suffering from a glioblastoma (GBM) by administering to the patient an effective amount of temozolomide, wherein a mass spectrometry analysis of... |
|
|
10725042 |
Methods of diagnosing and treating cancer
A method of determining the susceptibility of a cancer in a subject to treatment with an antimetabolite includes obtaining a sample of cancer cells from the subject, measuring the level of UDG... |
|
|
10725023 |
Method of measuring cell-substrate impedance in living cells to identify compounds affecting receptor tyrosine kinase (RTK) activity and pathways for the treatment of cancer
A method of identifying a therapeutic compound for treating cancer in a human subject, the method including: providing a device that measures cell-substrate impedance; culturing cancer cells in... |
|
|
10724102 |
Point mutations in TRK inhibitor-resistant cancer and methods relating to the same
Provided herein are methods of treating a subject having a cancer, methods of selecting a treatment for a subject having a cancer, methods of selecting a subject having a cancer for a treatment... |
|
|
10724101 |
Biomarker SCNN1B for gastric cancer
The present invention provides a method for diagnosing and determining prognosis of gastric cancer in a subject by detecting suppressed expression of the SCNN1B gene, which in some cases is due to... |
|
|
10724100 |
Systems and methods for treating patients having a genetic predisposition to develop prostate cancer
Systems and methods for mitigating prostate cancer development are provided. Peripheral blood cells may be evaluated for the presence or quantity of gamma-H2AX foci, and/or for gene alterations... |
|
|
10723756 |
Cyclic dinucleotides for treating conditions associated with STING activity such as cancer
This disclosure features chemical entities (e.g., a compound that modulates (e.g., agonizes) Stimulator of Interferon Genes (STING), or a pharmaceutically acceptable salt, and/or hydrate, and/or... |
|
|
10723748 |
Monomaleimide-functionalized platinum compounds for cancer therapy
The present invention relates to novel monomaleimide-functionalized platinum compounds of formula (I), including in particular novel monomaleimide-functionalized oxaliplatin and carboplatin... |
|
|
10722600 |
Methods and compositions for treating cancer
The present invention relates to the use of NS1/2 region of murine norovirus MNV or a corresponding region from a member of the Caliciviridae family or a protein encoded by any one of those... |
|
|
10722593 |
Anti-cancer compounds and conjugates thereof
Disclosed are compounds based on dolastatins, drug-conjugates, methods of preparing drug-conjugates, and uses thereof. Also disclosed are pharmaceutical compositions and methods of treatment. The... |
|
|
10722538 |
Peptides and combination of peptides for use in immunotherapy against epithelial ovarian cancer and other cancers
The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The... |
|
|
10722537 |
Activation of resident memory T cells for cancer immunotherapy
Provided herein are methods of treating cancer by activating resident memory T cells using one or more antigenic peptides. |
|
|
10722531 |
OPRT expression and cancer treatment outcome
Improved methods for treating cancer are provided herein by determining if a cancer patient, particularly a colon cancer patient or a gastric cancer patient, will clinically respond in a favorable... |
|
|
10722530 |
Methods of diagnosing and treating cancer
A method of treating cancer in a subject includes determining the p53 status and the level of UDG in cancer cells of the subject and administering an antimetabolite agent in combination with an AP... |
|
|
10722523 |
Chemoimmunotherapy for epithelial cancer
The invention provides a method for treating cancer in a subject in need thereof, wherein said subject comprises cancer tissue that ‘contains epithelial cancer cells and immunosuppressive 8 cells,... |
|
|
10722515 |
Dual CLK/CDK1 inhibitors for cancer treatment
The disclosure generally relates to substituted purine analogs that are dual CLK2/CDK1 inhibitors or more potent and specific CLK inhibitors to target CLK2 and CDK1 kinases. These compounds may be... |
|
|
10722484 |
Methods of cancer treatment
This present disclosure is directed to a method of treating a subject with cancer with a combination of a protein kinase C (PKC) activator and a second therapeutic agent. |
|
|
10722480 |
Agent for controlling cells constituting cancer microenvironment or inflammatory microenvironment
An agent according to the present invention comprises as an effective component any of (1) disulfiram, diethyldithiocarbamate, or a metal complex of diethyldithiocarbamate; (2) a pharmaceutically... |
|
|
10722466 |
Liposomal formulation for use in the treatment of cancer
The invention relates to a pharmaceutical liposomal composition comprising 2-{[5-{3-chloro-2-methyl-4-[2-(4-methylpiperazin-1-yl)ethoxy
]phenyl}-6-(4-fluorophenyl)thieno... |
|
|
10718774 |
Methods and compositions for assessing germline risk of cancer
Heritable mutations in the BRCA1 and BRCA2 and other genes in the DNA double-strand break (DSB) repair pathway increase risk of breast, ovarian and other cancers. In response to DNA breaks, the... |
|
|
10718030 |
Methods for predicting effectiveness of chemotherapy for a breast cancer patient
The present invention relates to a method of predicting the effectiveness of chemotherapy in a breast cancer patient, and more particularly, to a method for predicting the effectiveness of... |
|
|
10717780 |
Agents for treatment of claudin expressing cancer diseases
The present invention provides binding agents that contain n binding domain that is specific for CD3 allowing binding to T cells and a binding domain that is specific for a tumor-associated... |
|
|
10717724 |
Compounds useful for treating cancer
The present invention relates to a compound of formula (I): wherein A and A′ independently represent a phenylene group or a pyridylene group; R2 is a hydrogen atom or a (C1-C4)alkyl group; R3 is a... |
|
|
10717722 |
Acyl sulfonamides that are Bcl family antagonists for use in clinical management of conditions caused or mediated by senescent cells and for treating cancer
The aryl sulfonamide compounds of this invention have powerful and cell-type specific Bcl inhibitory activity. Compounds of this invention include compounds according to formula (I): Selected... |
|
|
10716868 |
Imaging of metastatic or recurrent cancer
The present disclosure relates to methods of administering [18F]-FACBC. The present disclosure also relates to use of [18F]-FACBC in methods for imaging, diagnosing and monitoring metastasis or... |
|
|
10716861 |
Composition intended to vectorise an anti-cancer agent
A composition in the form of a water-in-oil emulsion comprising: from 20% to 40% (v/v) of aqueous phase, in the form of droplets, comprising an anti-cancer agent and a densifying agent chosen from... |
|
|
10716837 |
Methods and compositions relating to P62 for the treatment and prophylaxis of cancer
Provided herein are novel p62 compositions for the prophylaxis and treatment of cancer and related methods. The invention also provides modified p62 compositions that increase the anti-cancer... |
|
|
10716826 |
Compositions for overcoming anti-cancer drug-resistance or compositions for anti-cancer activity employing CAGE-derived peptides
A pharmaceutical anticancer or anticancer drug-resistance composition for a cancer cell, containing a CAGE-derived peptide, is provided. The pharmaceutical anticancer composition contains an... |